Warning! GuruFocus detected
1 Severe warning sign
with MDXG.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
MiMedx Group Inc
NAICS : 541713
SIC : 2834
ISIN : US6024961012
Description
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.55 | |||||
| Equity-to-Asset | 0.73 | |||||
| Debt-to-Equity | 0.1 | |||||
| Debt-to-EBITDA | 0.29 | |||||
| Interest Coverage | 46.08 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 10.69 | |||||
| Beneish M-Score | -2.81 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 2.2 | |||||
| 3-Year Book Growth Rate | 995.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 16.03 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 10.67 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 51.79 | |||||
| 9-Day RSI | 41.6 | |||||
| 14-Day RSI | 38.84 | |||||
| 3-1 Month Momentum % | -7.85 | |||||
| 6-1 Month Momentum % | 41.86 | |||||
| 12-1 Month Momentum % | 25.97 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.21 | |||||
| Quick Ratio | 3.69 | |||||
| Cash Ratio | 2.29 | |||||
| Days Inventory | 144.11 | |||||
| Days Sales Outstanding | 57.24 | |||||
| Days Payable | 49.44 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9.5 | |||||
| Shareholder Yield % | 3.24 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 82.78 | |||||
| Operating Margin % | 17 | |||||
| Net Margin % | 12.16 | |||||
| FCF Margin % | 18.49 | |||||
| ROE % | 25.23 | |||||
| ROA % | 17.69 | |||||
| ROIC % | 30.25 | |||||
| 3-Year ROIIC % | 87.26 | |||||
| ROC (Joel Greenblatt) % | 109.63 | |||||
| ROCE % | 29.94 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 24.29 | |||||
| Forward PE Ratio | 24.73 | |||||
| PE Ratio without NRI | 22.59 | |||||
| Price-to-Owner-Earnings | 18.93 | |||||
| PS Ratio | 2.88 | |||||
| PB Ratio | 5.19 | |||||
| Price-to-Tangible-Book | 6.18 | |||||
| Price-to-Free-Cash-Flow | 15.62 | |||||
| Price-to-Operating-Cash-Flow | 15.19 | |||||
| EV-to-EBIT | 15.47 | |||||
| EV-to-EBITDA | 14.03 | |||||
| EV-to-Revenue | 2.61 | |||||
| EV-to-Forward-Revenue | 2.56 | |||||
| EV-to-FCF | 14.11 | |||||
| Price-to-GF-Value | 1.09 | |||||
| Price-to-Projected-FCF | 7.39 | |||||
| Price-to-Median-PS-Value | 0.97 | |||||
| Price-to-Graham-Number | 2.49 | |||||
| Price-to-Net-Current-Asset-Value | 8.29 | |||||
| Price-to-Net-Cash | 29.57 | |||||
| Earnings Yield (Greenblatt) % | 6.46 | |||||
| FCF Yield % | 6.44 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MDXG
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
MiMedx Group Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 348.88 | ||
| EPS (TTM) ($) | 0.28 | ||
| Beta | 1.5 | ||
| 3-Year Sharpe Ratio | 0.47 | ||
| 3-Year Sortino Ratio | 0.9 | ||
| Volatility % | 53.84 | ||
| 14-Day RSI | 38.84 | ||
| 14-Day ATR ($) | 0.29534 | ||
| 20-Day SMA ($) | 7.046 | ||
| 12-1 Month Momentum % | 25.97 | ||
| 52-Week Range ($) | 5.47 - 10.14 | ||
| Shares Outstanding (Mil) | 147.37 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
MiMedx Group Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
MiMedx Group Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
MiMedx Group Inc Frequently Asked Questions
What is MiMedx Group Inc(MDXG)'s stock price today?
The current price of MDXG is $6.80. The 52 week high of MDXG is $10.14 and 52 week low is $5.47.
When is next earnings date of MiMedx Group Inc(MDXG)?
The next earnings date of MiMedx Group Inc(MDXG) is 2025-04-30.
Does MiMedx Group Inc(MDXG) pay dividends? If so, how much?
MiMedx Group Inc(MDXG) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers